Latest Updates

    None Found

Seaside Therapeutics are Tackling Fragile X

This weeks C&EN magazine has an article about Seaside Therapeutics and their unique funding stream which allows them to avoid cutting corners and focus on on basic research and early tests for their Fragile X and autism treatment studies.

Tackling Fragile X

September 13, 2010 | Volume 88, Number 37 | pp. . . . » Continue reading

Cambridge's Seaside Therapeutics Reports Positive Data from study

Seaside Therapeutics Reports Positive Data from Phase 2 Study of STX209 in Autism Spectrum Disorders

–Study of STX209 to advance in autism spectrum disorders–

CAMBRIDGE, MASS., September 9, 2010—Seaside Therapeutics, Inc. announced today positive data from an open-label Phase 2 study of STX209 conducted in patients with autism spectrum disorders (ASD). The primary endpoint of the study, an improvement on the Irritability subscale of the Aberrant Behavior Checklist (ABC-I), achieved statistical significance (p<0.001). In addition, STX209 demonstrated statistically significant improvements across a number of other global and specific neurobehavioral outcomes, including improvements on the Social Withdrawal subscale of the Aberrant Behavior Checklist (ABC-SW, p<0.001), which assesses a core symptom of ASD. A significant number of patients enrolled in the study are participating in an open-label extension study. STX209 is a selective gamma-amino butyric acid type B (GABA-B) receptor agonist being studied for the treatment of ASD and fragile X syndrome (FXS). In July 2010, Seaside reported clinically meaningful data from a randomized, placebo-controlled study of STX209 in individuals with FXS. The Company intends to present the full results from both studies at future medical meetings.

“We observed marked improvement in the majority of patients treated in the STX209 autism spectrum disorders study, including reductions in agitation and tantrums,” said Craig A. Erickson, M.D., Assistant Professor of Psychiatry, Chief of the Christian Sarkine Autism Treatment Center, Chief of the Fragile X Research Treatment Center at the Indiana University School of Medicine and an investigator in the study. “STX209 was well tolerated and most study participants continue to receive treatment in an open-label extension study. The importance of novel therapeutic development in neurodevelopmental disorders such as autism spectrum disorders and fragile X syndrome cannot be underestimated. This work will potentially open up a door to treating disorders that has, until recently, been firmly shut.”

“These study results add to a growing body of evidence supporting the potential of STX209 to play an important role in treating neurodevelopment disorders such as fragile X syndrome and autism spectrum disorders,” said Randall L. Carpenter, M.D., President and Chief Executive Officer of Seaside Therapeutics. “In addition, we have now observed significant improvement in social interaction across two studies. We believe the reduction in social withdrawal is important as it suggests that STX209 is demonstrating efficacy for a core symptom of both fragile X syndrome and autism. We look forward to initiating later stage clinical studies of STX209 in both fragile X syndrome and autism spectrum disorders.”

. . . » Continue reading

Scientists Identify New Drug Strategy Against Fragile X Syndrome

Scientists identify new drug strategy against fragile X syndrome

Contact: Jennifer Johnson jrjohn9@emory.edu 404-727-5696 Emory University

Researchers at Emory University School of Medicine have identified a potential new strategy for treating fragile X syndrome, the most common inherited cause of intellectual disability.

The researchers have found that a class of drugs called . . . » Continue reading

UC Davis MIND Institute: Drug appears to aid children with fragile X syndrome (Minocycline)

New survey study results from UC Davis.

Drug appears to aid children with fragile X syndrome

Date: 2010-08-31 Contact: Phyllis Brown Phone: (916) 734-9023 Email: phyllis.brown@ucdmc.ucdavis.edu

SACRAMENTO — One of the antibiotics most commonly prescribed to treat adolescent acne can increase attention spans and communication and decrease anxiety in patients with fragile . . . » Continue reading

New, Family-Friendly FXTAS Website Launched!

The National Fragile X Foundation (NFXF) has launched a new web-site devoted entirely to helping those impacted by fragile X-associated tremor ataxia syndrome (FXTAS) and the professionals who work with them. Already many hundreds of individuals have accessed the information developed by a committee of professionals, family members and web specialists. If you, your . . . » Continue reading

Cambridge's Seaside has new approach to Fragile X

The following article was published in The Boston Globe on August 23, 2010.

Matthew’s liberation Seaside at forefront of new approach to Fragile X

By Karen Weintraub Globe Correspondent/August 23, 2010

It was the week the medication didn’t work that convinced Melissa Zolecki. She thinks her son Matthew got a bottle of inactive dummy . . . » Continue reading